TRANSTHERA-B (02617) Selected for Inclusion in Hang Seng Index Series

Stock News
Aug 25

TRANSTHERA-B (02617) announced that following the quarterly review results published by Hang Seng Indexes Company Limited on August 22, 2025, the company has been selected for inclusion in various Hang Seng index series, effective September 8, 2025.

The company will be included in the following indices: 1. Hang Seng Composite Index; 2. Hang Seng Composite Industry Index - Healthcare; 3. Hang Seng Composite MidCap & SmallCap Index; 4. Hang Seng Composite SmallCap Index; 5. Hang Seng Healthcare Index; 6. Hang Seng Biotech Index; 7. Hang Seng Stock Connect Biotech Index; 8. Hang Seng Stock Connect Biotech Select Index; and 9. Hang Seng Stock Connect Pharmaceuticals & Biotechnology (Investable) Index.

The company stated that its inclusion in the Hang Seng Composite Index and the aforementioned indices reflects rising investor recognition.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10